Luis M Real

Dr. Luis M Real

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BKBrian W. Kunkle
Brian W. Kunkle
T(The European Alzheimer’s Disease Initiative (Eadi)
The European Alzheimer’s Disease Initiative (Eadi)
BGBenjamin Grenier-Boley
Benjamin Grenier-Boley
RSRebecca Sims
Rebecca Sims
JBJoshua C. Bis
Joshua C. Bis
MPMargaret A. Pericak-Vance
Margaret A. Pericak-Vance

4 April 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CBCéline Bellenguez
Céline Bellenguez
FKFahri Küçükali
Fahri Küçükali
IJIris E. Jansen
Iris E. Jansen
LKLuca Kleineidam
Luca Kleineidam
SMSonia Moreno-Grau
Sonia Moreno-Grau
JLJean-Charles Lambert
Jean-Charles Lambert
Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/‘proxy’ AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.

20 April 2019 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
ABAntonio Boza-Serrano
Antonio Boza-Serrano
RLRocío Ruiz Laza
Rocío Ruiz Laza
RSRaquel Sanchez-Varo
Raquel Sanchez-Varo
JGJuan García-Revilla
Juan García-Revilla
YYYiyi Yang
Yiyi Yang
TDTomas Deierborg
Tomas Deierborg
Alzheimer’s disease (AD) is a progressive neurodegenerative disease in which the formation of extracellular aggregates of amyloid beta (Aβ) peptide, fibrillary tangles of intraneuronal tau and microglial activation are major pathological hallmarks. One of the key molecules involved in microglial activation is galectin-3 (gal3), and we demonstrate here for the first time a key role of gal3 in AD pathology. Gal3 was highly upregulated in the brains of AD patients and 5xFAD (familial Alzheimer’s disease) mice and found specifically expressed in microglia associated with Aβ plaques. Single-nucleotide polymorphisms in the LGALS3 gene, which encodes gal3, were associated with an increased risk of AD. Gal3 deletion in 5xFAD mice attenuated microglia-associated immune responses, particularly those associated with TLR and TREM2/DAP12 signaling. In vitro data revealed that gal3 was required to fully activate microglia in response to fibrillar Aβ. Gal3 deletion decreased the Aβ burden in 5xFAD mice and improved cognitive behavior. Interestingly, a single intrahippocampal injection of gal3 along with Aβ monomers in WT mice was sufficient to induce the formation of long-lasting (2 months) insoluble Aβ aggregates, which were absent when gal3 was lacking. High-resolution microscopy (stochastic optical reconstruction microscopy) demonstrated close colocalization of gal3 and TREM2 in microglial processes, and a direct interaction was shown by a fluorescence anisotropy assay involving the gal3 carbohydrate recognition domain. Furthermore, gal3 was shown to stimulate TREM2–DAP12 signaling in a reporter cell line. Overall, our data support the view that gal3 inhibition may be a potential pharmacological approach to counteract AD.

7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
IRItziar de Rojas
Itziar de Rojas
SMSonia Moreno-Grau
Sonia Moreno-Grau
NTNiccolo Tesi
Niccolo Tesi
BGBenjamin Grenier-Boley
Benjamin Grenier-Boley
VAVictor Andrade
Victor Andrade
ARAgustín Ruiz
Agustín Ruiz
Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer’s disease.

28 August 2019 in Alzheimer's & Dementia
Verified
Journal Article
Open access
SMSonia Moreno‐Grau
Sonia Moreno‐Grau
IRItziar de Rojas
Itziar de Rojas
IHIsabel Hernández
Isabel Hernández
IQInés Quintela
Inés Quintela
LMLaura Montrreal
Laura Montrreal
ARAgustín Ruiz
Agustín Ruiz
Introduction: Large variability among Alzheimer's disease (AD) cases might impact genetic discoveries and complicate dissection of underlying biological pathways.Methods: Genome Research at Fundacio ACE (GR@ACE) is a genome‐wide study of dementia and its clinical endophenotypes, defined based on AD's clinical certainty and vascular burden. We assessed the impact of known AD loci across endophenotypes to generate loci categories. We incorporated gene coexpression data and conducted pathway analysis per category. Finally, to evaluate the effect of heterogeneity in genetic studies, GR@ACE series were meta‐analyzed with additional genome‐wide association study data sets.Results: We classified known AD loci into three categories, which might reflect the disease clinical heterogeneity. Vascular processes were only detected as a causal mechanism in probable AD. The meta‐analysis strategy revealed the ANKRD31‐rs4704171 and NDUFAF6‐rs10098778 and confirmed SCIMP‐rs7225151 and CD33‐rs3865444.Discussion: The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta‐analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series.

11 June 2008 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
RCRafael Carretero
Rafael Carretero
JRJosé M. Romero
José M. Romero
FRFrancisco Ruiz-Cabello
Francisco Ruiz-Cabello
IMIsabel Maleno
Isabel Maleno
FRFelix Rodriguez
Felix Rodriguez
TCTeresa Cabrera
Teresa Cabrera